Dennis H. Giesing
Equibles does not estimate personal net worth.
About Dennis H. Giesing
Immunome Inc. reported in an 8-K filed October 4, 2023 that Dennis H. Giesing was terminated as Immunome's former Chief Development Officer, effective October 2, 2023. The proxy statement of Immunome Inc. reports total compensation of $3,499,917 for Dennis H. Giesing in fiscal 2021, including a base salary of $306,971.
“(iii) Dennis Giesing, Ph.D., Immunome's former Chief Development Officer, was terminated as an officer and employee of Immunome effective as of the closing of the Merger.”
Affiliation history
-
Immunome Inc. (IMNM)
Proxy statement
Start not stated–2023-10-02
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Immunome Inc. (IMNM) | Chief Development Officer | $306,971 | $3,499,917 |